TScan Therapeutics (NASDAQ:TCRX) Issues Quarterly Earnings Results

TScan Therapeutics (NASDAQ:TCRX) posted its quarterly earnings results on Thursday. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06), FiscalAI reports. The firm had revenue of $0.59 million for the quarter, compared to analysts’ expectations of $0.46 million. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%.

TScan Therapeutics Stock Performance

TCRX traded down $0.01 during midday trading on Thursday, hitting $0.17. 366,561 shares of the company were exchanged, compared to its average volume of 717,536. The company’s 50 day simple moving average is $0.27 and its 200 day simple moving average is $0.81. The firm has a market capitalization of $11.66 million, a price-to-earnings ratio of -0.19 and a beta of 1.21. TScan Therapeutics has a 1-year low of $0.17 and a 1-year high of $1.47. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.31.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on TCRX shares. Benchmark reaffirmed a “buy” rating on shares of TScan Therapeutics in a report on Thursday, August 13th. Weiss Ratings downgraded shares of TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Lifesci Capital lowered shares of TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. HC Wainwright cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price objective for the company. in a research note on Tuesday, September 8th. Finally, Wedbush cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price objective for the company. in a research note on Wednesday, September 2nd. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, TScan Therapeutics currently has an average rating of “Hold” and a consensus target price of $2.67.

About TScan Therapeutics

TScan Therapeutics, Inc. is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its approach involves genetically modifying a patient’s T cells to recognize specific cancer-related antigens, with the goal of directing the immune system to attack malignant cells. The company’s pipeline includes investigational therapies for hematologic malignancies and solid tumors. Its lead programs, TSC-100 and TSC-101, are designed to target the HA-1 antigen in patients with certain blood cancers following an allogeneic hematopoietic stem cell transplant.